AR064359A1 - Agregados de lipidos polares de arqueas para administracion a animales - Google Patents

Agregados de lipidos polares de arqueas para administracion a animales

Info

Publication number
AR064359A1
AR064359A1 ARP070105629A ARP070105629A AR064359A1 AR 064359 A1 AR064359 A1 AR 064359A1 AR P070105629 A ARP070105629 A AR P070105629A AR P070105629 A ARP070105629 A AR P070105629A AR 064359 A1 AR064359 A1 AR 064359A1
Authority
AR
Argentina
Prior art keywords
administration
mucosal
antigen
compositions
composition according
Prior art date
Application number
ARP070105629A
Other languages
English (en)
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of AR064359A1 publication Critical patent/AR064359A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones no replicadoras, y métodos para la administracion de estas composiciones que contienen productos farmacéuticos, moléculas biologicamente relevantes y/o antígenos al huésped, por administracion por una vía mucosa tal como la intranasal. Esta solicitud provee composiciones de vacunas no replicadoras y métodos para la administracion de antígenos en estas composiciones de vacuna que comprenden un antígeno y un vehículo auto-adyuvante, utiles para inducir respuestas inmunes en mucosas y sistémicas antígeno-especificas en el huésped tras la inmunizacion mediante una vía mucosa tal como la intranasal. Las composiciones de vacuna comprenden cationes multivalentes en asociacion con una pluralidad de agregados lipídicos esféricos polares de arqueobacterias que contienen comportamientos acuosos, la estructura de AMVAD(estructura de administracion de vacuna mucosa y adyuvante mucoso lipídico/cationico polar arqueal), formada por la interaccion de arqueosomas y antígeno(s) con cationes multivalentes tales como Ca2+, donde la estructura de AMVAD actua como un vehículo auto-adyuvante para el(los) antígeno(s) en la composicion de vacuna. Ciertas respuestas inmunes ventajosas también se pueden desarrollar con las presentes composiciones. Reivindicacion 8: Una composicion de acuerdo con la realizacion 6, donde la especie de arqueobacteria es Methanobrevibacter smithii. Reivindicacion 10:.Una composicion de acuerdo con la realizacion 6, donde la especie de arqueobacteria es Thermoplasrna acidophillum. Reivindicacion 15: Una composicion de acuerdo con la realizacion 14, donde los arqueosomas unilaminares preparados en el paso a) se preparan vacíos y el agente farmacéutico, la molécula biologicamente relevante o un componente antigénico luego se mezclan con la preparacion de arqueosomas antes de continuar con el paso b) Reivindicacion 28: Una composicion de acuerdo con la realizacion 26, donde la especie de arqueobacteria es Halobacterium salinarum. Reivindicacion 37: Una composicion preparada de acuerdo con la realizacion 34, donde en el paso c) el componente antigénico libre y soluble no se retira.
ARP070105629A 2006-12-15 2007-12-14 Agregados de lipidos polares de arqueas para administracion a animales AR064359A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87530506P 2006-12-15 2006-12-15

Publications (1)

Publication Number Publication Date
AR064359A1 true AR064359A1 (es) 2009-04-01

Family

ID=39511198

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105629A AR064359A1 (es) 2006-12-15 2007-12-14 Agregados de lipidos polares de arqueas para administracion a animales

Country Status (6)

Country Link
US (2) US20080220028A1 (es)
EP (1) EP2109459B1 (es)
AR (1) AR064359A1 (es)
CA (1) CA2672338C (es)
TW (1) TW200833709A (es)
WO (1) WO2008070982A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740716A1 (en) * 2008-10-14 2010-04-22 Dow Agrosciences Llc Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc)
MX347400B (es) * 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
EP2968147A4 (en) * 2013-03-15 2017-02-22 The Penn State Research Foundation Acid stable liposomal compositions
EP3166957B1 (en) 2014-07-11 2019-11-13 National Research Council of Canada Sulfated-glycolipids as adjuvants for vaccines
EP3708151A1 (en) 2019-03-15 2020-09-16 Technische Universität Wien Method for producing a composition comprising archaeal lipids from a sulfolobus cell culture
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US5643574A (en) 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US6132789A (en) 1995-12-15 2000-10-17 National Research Council Of Canada Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles
CU22629A1 (es) 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
US6340591B1 (en) 1998-12-14 2002-01-22 University Of Maryland Integrative protein-DNA cochleate formulations and methods for transforming cells
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
CA2389652A1 (en) 1999-10-12 2001-04-19 National Research Council Of Canada Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte(ctl) responses and protect the vaccinated host against intracellular pathogens and cancer
JP2003529557A (ja) 2000-01-24 2003-10-07 バイオデリバリー サイエンス インコーポレーテッド コクリエート製剤、その調製方法および生物学的関連分子投与のための用途
US20030219473A1 (en) 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
US8758763B2 (en) 2014-06-24
US20130195932A1 (en) 2013-08-01
EP2109459A4 (en) 2011-03-30
EP2109459A1 (en) 2009-10-21
CA2672338C (en) 2017-06-06
WO2008070982A1 (en) 2008-06-19
TW200833709A (en) 2008-08-16
EP2109459B1 (en) 2013-03-06
US20080220028A1 (en) 2008-09-11
CA2672338A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
AR064359A1 (es) Agregados de lipidos polares de arqueas para administracion a animales
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
Guo et al. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant
AR072378A1 (es) Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos.
EA200701787A1 (ru) Иммунная композиция, способ ее изготовления, ее применение и способ вакцинации
Li et al. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
AR053360A1 (es) Formulaciones novedosas de vacunas
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
HRP20140488T1 (hr) Cjepivo protiv influence
AR090294A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
BR112013000244A2 (pt) lipossomas com lipídeos apresentando pka vantajoso para administração de rna
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
PE20120319A1 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico
CL2013001833A1 (es) Composicion inmunomoduladora que comprende un vehiculo de administracion de liposoma cationico y una molecula de acido nucleico; y su uso para tratar una enfermedad respiratoria bovina en el ganado.
BRPI0512757A (pt) método de estabilização de lipossomos catiÈnicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamìdia, malária ou tuberculose e sistema de distribuição
Kitaoka et al. Sucrose laurate-enhanced transcutaneous immunization with a solid-in-oil nanodispersion
AR053661A1 (es) Peptido para entregar vacunas via mucosas
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
Kimoto et al. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice

Legal Events

Date Code Title Description
FB Suspension of granting procedure